Malignant peripheral nerve sheath tumors (MPNST): A SEER analysis of incidence across the age spectrum and therapeutic interventions in the pediatric population

Pediatric Blood and Cancer

Volumn 61, Issue 11, 2014, Pages 1955-1960

  Bates, James E ^a   Peterson, Carl R ^b   Dhakal, Sughosh ^b   Giampoli, Ellen J ^b   Constine, Louis S ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Incidence; Malignant peripheral nerve sheath tumors; Radiation therapy; SEER; Survival

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHILD; COMPARATIVE STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; RACE; UNITED STATES; CANCER REGISTRY; INCIDENCE; MORTALITY; MULTIVARIATE ANALYSIS; NERVE SHEATH NEOPLASMS; NEWBORN; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, NEUROFIBROMATOSIS 1; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MULTIVARIATE ANALYSIS; NERVE SHEATH NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM;

EID: 84922681150     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25149     Document Type: Article

References (37)

1. Miser JS, Pappo AS, Triche TJ, et al. Principles and practice of pediatric oncology, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2002. pp. 1017-1050.
2. Enzinger FM, Weiss SW. Soft tissue tumors, 4th ed. St. Louis: Mosby; 2001. pp. 1209-1263.
3. Yohay K. Neurofibromatosis type 1 and associated malignancies. Curr Neurol Neurosci Rep 2009; 9:247-253.
4. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006-2021.
5. Casanova M, Ferrari A, Spreafico F, et al. Malignant peripheral nerve sheath tumors in children: A single-institution twenty-year experience. J Pediatr Hematol Oncol 1999; 21:509-513.
6. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 2005; 23:8422-8430.
7. deCou JM, Rao BN, Parham DM, et al. Malignant peripheral nerve sheath tumors: The St. Jude Children's Research Hospital experience. Ann Surg Oncol 1995; 2:524-529.
8. Demir HA, Varan A, Yalcn B, et al. Malignant peripheral nerve sheath tumors in childhood: 13 cases from a single center. J Pediatr Hematol Oncol 2012; 34:204-207.
9. Raney B, Schanufer L, Ziegler M, et al. Treatment of children with neurogenic sarcoma: Experience at the Children's Hospital of Philadelphia, 1958-1984. Cancer 1987; 59:1-5.
10. Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): The Mayo Clinic experience. Ann Surg Oncol 2012; 19:878-885.
11. Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Pediatr Drugs 2007; 9:239-248.
12. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission.
13. Adamo MB, Johnson CH, Ruhl JL, et al. editors. SEER program coding and staging manual. Bethesda, MD: National Cancer Institute; 2012. NIH Pub. No. 12-5581.
14. Spunt SL, Skapek SX, Coffin CM. Pediatric nonrhadbomyosarcoma soft tissue sarcomas. Oncologist 2008; 13:668-678.
15. Spunt SL, Pappo AS. Childhood nonrhabdomyosarcoma soft tissue sarcomas are not adult-type tumors. J Clin Oncol 2006; 24:1958-1959.
16. Ferrari A, Miceli R, Rey A, et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. Eur J Cancer 2011; 47:724-731.
17. Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol 2013; 15:135-147.
18. Nakamura JL, Phong C, Pinarbasi E, et al. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res 2011; 71:106-115.
19. Grill J, Couanet D, Cappelli C, et al. Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 1999; 45:393-396.
20. Jamjoom AB, Malabarey T, Jamjoom ZA, et al. Cerebro-vasculopathy and malignancy: Catastrophic complications of radiotherapy for optic nerve glioma in a von Recklinghausen neurofibromatosis patient. Neurosurg Rev 1996; 19:47-51.
21. Wentworth S, Pinn M, Bourland JD, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associcated central nervous system tumors. Int J Radiat Oncol Biol Phys 2009; 73:208-213.
22. Li H, Zhang X, Fishbein L, et al. Analysis of steroid hormone effects on xenografted human NF1 tumor Schwann cells. Cancer Biol Ther 2010; 10:758-764.
23. Waxweiler TV, Proper MS, Rusthoven C, et al. Nonrhabdomyosarcoma soft tissue sarcomas in children: A Surveillance, Epidemiology, and End Results analysis. Int J Radiat Oncol Biol Phys 2013; 87:S71.
24. Amirian ES, Goodman JC, New P, et al. Pediatric and adult malignant peripheral nerve sheath tumors: An analysis of data from the Surveillance, Epidemiology, and End Results program. J Neurooncol 2014; 116:609-616.
25. Benz MR, Czernin J, Dry SM, et al. Quantitiative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 2010; 116:451-458.
26. Treglia G, Taralli S, Bertagna F, et al. Usefulness of whole-body fluorine-18-deoxyglucose positron emission tomography in patients with neurofibromatosis Type 1: A systematic review. Radiol Res Pract 2012; 43:1029.
27. Combemale P, Valeyrie-Allanore L, Giammarile F, et al. Utility of 18F-FDG PET with a semi-qualitative index in the detection of sarcomatous transformation in patients with neurofibromatosis Type 1. PLoS ONE 2014; 9:e85954.
28. Ferner RE, Lucas JD, O'Doherty MJ, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000; 68:353-357.
29. Meany H, Dombi E, Reynolds J, et al. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis Type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer 2013; 60:59-64.
30. Park SJ, Sawitzki B, Kluwe L, et al. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med 2013; 11:109.
31. Itani S, Kunisada T, Morimoto Y, et al. MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein (PDCD4). J Cancer Res Clin Oncol 2012; 138:1501-1509.
32. Keng VW, Rahrmann EP, Watson AL, et al. PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res 2012; 72:3405-3413.
33. Alaggio R, Turrini R, Boldrin D, et al. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). PLoS ONE 2013; 8:e80456.
34. Krasin MJ, Davidoff AM, Xiong X, et al. Preliminary results from a prospective study using limited margin radiotherapy in pediatric and young adult patients with high-grade nonrhabdomyosarcoma soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2010; 76:874-878.
35. Timmermann B, Schuck A, Niggli F, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2007; 67:497-504.
36. Jagsi R, Abrahamse P, Hawley ST, et al. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer 2012; 118:333-341.
37. Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist 2014; 19:193-201.